ReviewAnnals of the American Thoracic Society2016
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Review in Annals of the American Thoracic Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2024Pooled it
- Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.Annals of the rheumatic diseases · 2019Trial
- Nailfold Capillaroscopy Patterns Are Associated with Impairment of DLCO in Very Early Diagnosis of Systemic Sclerosis: Insights of a Pulmonary-Vascular Interplay.Diagnostics (Basel, Switzerland) · 2026Article
- Pulmonary Function Decline in Very Early Diagnosis of Systemic Sclerosis: A Retrospective Longitudinal Single-Center Study.ACR open rheumatology · 2026Article
- Review
- Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis.Archives of rheumatology · 2025Article
- Systemic Sclerosis with Interstitial Lung Disease: Identification of Novel Immunogenetic Markers and Ethnic Specificity in Kazakh Patients.Epidemiologia (Basel, Switzerland) · 2025Article
- Influence of metabolic factors on systemic sclerosis complicated with severe interstitial lung disease based on high-resolution computed tomography grading.Clinical rheumatology · 2025Article
- CD45+/ Col I+ Fibrocytes: Major source of collagen in the fibrotic lung, but not in passaged fibroblast cultures.Matrix biology : journal of the International Society for Matrix Biology · 2025Article
- Oral submucous fibrosis: pathogenesis and therapeutic approaches.International journal of oral science · 2025Review
- Review
- Therapeutic Approaches for the Treatment of Interstitial Lung Disease: An Exploratory Review on Molecular Mechanisms.Mini reviews in medicinal chemistry · 2024Review
- Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease.Annals of medicine · 2023Article
- Type 2 cytokines and scleroderma interstitial lung disease.Clinical and experimental medicine · 2023Article
- Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.Clinical reviews in allergy & immunology · 2022Review
- Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment.Rheumatology (Oxford, England) · 2022Article
- Kidney Involvement in Systemic Sclerosis.Journal of personalized medicine · 2022Review
- B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease.Mediterranean journal of rheumatology · 2022Review
- Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease.Clinical rheumatology · 2021Article
- Natural variability in the disease course of SSc-ILD: implications for treatment.European respiratory review : an official journal of the European Respiratory Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although interstitial lung disease accounts for the majority of deaths of patients with systemic sclerosis, treatment options for this manifestation of the disease are limited. Few high-quality, randomized, controlled trials exist for systemic sclerosis-related interstitial lung disease, and historically, studies have favored the use of cyclophosphamide. However, the benefit of cyclophosphamide for this disease is tempered by its complex adverse event profile. More recent studies have demonstrated the effectiveness of mycophenolate for systemic sclerosis-related interstitial lung disease, including Scleroderma Lung Study II. This review highlights the findings of this study, which was the first randomized controlled trial to compare cyclophosphamide with mycophenolate for the treatment of systemic sclerosis-related interstitial lung disease. The results reported in this trial suggest that there is no difference in treatment efficacy between mycophenolate and cyclophosphamide; however, mycophenolate appears to be safer and more tolerable than cyclophosphamide. In light of the ongoing advances in our understanding of the pathogenic mechanisms underlying interstitial lung disease in systemic sclerosis, this review also summarizes novel treatment approaches, presenting clinical and preclinical evidence for rituximab, tocilizumab, pirfenidone, and nintedanib, as well as hematopoietic stem cell transplantation and lung transplantation. This review further explores how reaching a consensus on appropriate study end points, as well as trial enrichment criteria, is central to improving our ability to judiciously evaluate the safety and efficacy of emerging experimental therapies for systemic sclerosis-related interstitial lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.